可能的capecitabine诱导的冠状动脉和心肌梗塞
Deepa Soodi1, Vinod Kumar Reddy Cirra2, Guruprasad D Naik3,1
1Cardiology, Marshfield Clinic Health System, Marshfield, USA.
Cureus
|May 9, 2025
概括
一种癌症药物卡佩奇他可以引起冠状动脉,导致心脏病发作. 及时识别和阻止这种心脏毒性对患者安全至关重要.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮他是一种广泛使用的口服化疗剂,是5-甲的前体.
- 它已被批准用于治疗各种癌症,包括乳腺癌和结直肠癌.
- 虽然有效,但了解其潜在的不良影响对于患者管理至关重要.
研究的目的:
- 报告一个罕见的capecitabine诱导的冠心血管的病例.
- 强调认识到与capecitabine治疗相关的心脏毒性的重要性.
- 要强调严重的心脏事件的潜力,如果这个不良影响被忽视.
主要方法:
- 一个77岁的乳腺癌女性患者接受capecitabine治疗的案例研究.
- 临床表现包括胸痛和心电图发现与急性前侧心肌梗塞一致.
- 冠状动脉扫描进行,以评估冠状动脉.
主要成果:
- 冠状动脉扫描显示了正常的冠状动脉,排除了阻塞性冠状动脉疾病.
- 患者的症状在停止服用capecitabine后完全消失.
- 这表明capecitabine与观察到的心脏事件之间存在直接联系.
结论:
- 卡佩奇他可以诱导冠状动脉,这是一种可能危及生命的心脏毒性.
- 早期识别和停止使用药物对于管理和预防严重的心脏并发症至关重要.
- 这一案例强调了在临床实践中对基酸诱导的心血管不良事件需要保持警.
相关概念视频
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
392
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
392
Imaging Studies for Cardiovascular System I:Echocardiography
267
Cardiac imaging studies encompass a wide range of noninvasive and minimally invasive techniques designed to visualize the heart's structure and function in detail. One such technique is echocardiography, which uses high-frequency ultrasound waves to produce detailed images of the heart, known as echocardiograms.
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
267
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.1K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.1K
Vascular Spasm
1.0K
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last...
1.0K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
692
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
692
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
392
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
392


